Found 4 results
Filters: Author is Ontaneda, Daniel  [Clear All Filters]
2021
Ontaneda D, Raza PC, Mahajan KR, Arnold DL, Dwyer MG, Gauthier SA, Greve DN, Harrison DM, Henry RG, Li DKB et al..  2021.  Deep grey matter injury in multiple sclerosis: a NAIMS consensus statement.. Brain. 144(7):1974-1984.
2020
Bagnato F, Gauthier SA, Laule C, Moore GRWayne, Bove R, Cai Z, Cohen-Adad J, Harrison DM, Klawiter EC, Morrow SA et al..  2020.  Imaging Mechanisms of Disease Progression in Multiple Sclerosis: Beyond Brain Atrophy.. J Neuroimaging. 30(3):251-266.
2018
Fox RJ, Coffey CS, Conwit R, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Naismith RT et al..  2018.  Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis.. N Engl J Med. 379(9):846-855.
2016
Fox RJ, Coffey CS, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Conwit R, Naismith R et al..  2016.  Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis.. Contemp Clin Trials. 50:166-77.